Cryptococcosis is a fungal infection which is caused by Cryptococcus neoformans and Cryptococcus gattii which primarily affects the central nervous system and the lungs. People with diseases such as AIDS, hodgkin lymphoma, other lymphomas, sarcoidosis, and solid organ transplantation with weakened immune systems are generally more susceptible to this type of infection.
Cryptococcosis is usually acquired by inhalation of dust containing yeast cells which typically affects the lungs. Cryptococcosis symptoms include fever, malaise, cough, hemoptysis (bloody or blood-tinged sputum), headache, vision changes (blurry or double vision, photophobia) etc. Cryptococcosis diagnosis is clinical and microscopic, which is confirmed by culture or fixed-tissue staining.
According to the United Nations Program on HIV/AIDS and the World Health Organization, globally approximately one million cases of cryptococcosis are reported each year resulting in 625,000 deaths approximately. According to the Centers for Disease Control and Prevention and WHO, it is estimated that globally every year 220,000 cases of cryptococcal meningitis occur among people with HIV/AIDS, resulting in nearly 181,000 deaths. Therefore with the growing prevalence of cryptococcosis and availability of advance treatment are the key factors that drives the growth of cryptococcosis diseases market. However, adverse effects associated with the use of medication is likely to restrain the market growth in the forecast period.
Key Market Trends
Flucytosine Segment is Expected to Hold a Significant Market Share
Flucytosine is a small, water-soluble molecule which is a nucleoside analog antifungal drug that acts by disrupting pyrimidine metabolism in the fungal cell nucleus. Flucytosine is generally given as first-line treatment in combination with other antifungal medications. Flucytosine was major revenue holding segment because it is given as first-line treatment in combination with other antifungal medications.
According to the United Nations Program on HIV/AIDS and the World Health Organization, globally approximately one million cases of cryptococcosis are reported each year resulting in 625,000 deaths approximately. The increasing prevalence of cryptococcosis and increasing new and advanced treatment opportunities are the key factors for the growth of the cryptococcosis market.
North America is Expected to Dominate the Market and Expected to do Same in the Forecast Period
North America is expected to hold a major share globally in cryptococcosis market due to the rising prevalence of cryptococcosis, the rise in technological advancements, and higher cost of medication in this region.
As per the study article published by National Institute of Health in 2019, in the United States prevalence of cryptococcosis is estimated to be about 0.4-1.3 cases per 100,000 population and 2-7 cases per 100,000 in people affected with AIDS with a case fatality ratio of about 12%. Therefore, North America holds a major market share due to the rising prevalence of cryptococcosis in the endemic areas that are fueling the growth of the overall regional market to a large extent.
Competitive Landscape
The Cryptococcosis Therapeutics Market is moderately consolidated and consists of several major players. In terms of market share, few of the major players are currently dominating the market. Some companies are adopting numerous strategies including acquisitions and collaborations to sustain market competition.
Reasons to Purchase this report:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support